目的：探讨布地奈德联合扎鲁司特治疗支气管哮喘的临床效果及对患者肺功能和炎性因子的影响。方法将106例本院收治的支气管哮喘患者根据入院时间结合随机数表法分为布地奈德＋扎鲁司特组（布地奈德联合扎鲁司特治疗）和布地奈德组（单纯布地奈德治疗），每组各53例。两组患者均采用哮喘常规内科治疗方案，7天为一疗程，共治疗2个疗程。结果布地奈德＋扎鲁司特组患者治疗后第一秒用力呼气量（FEV1）、第一秒用力呼气量占用力肺活量百分率（FEV1/FVC）及呼气流量峰值（PEF）均明显高于布地奈德组（P ＜0.01）；布地奈德＋扎鲁司特组患者治疗后白细胞介素（IL）-4、IL-8及肿瘤坏死因子-α（TNF-α）水平均明显低于布地奈德组（P ＜0.01）；布地奈德＋扎鲁司特组治疗总有效率明显高于布地奈德组（P ＜0.01）。结论布地奈德联合扎鲁司特可改善支气管哮喘患者肺通气功能，降低炎性因子水平，缓解哮喘症状。%Objective To explore the effect of budesonide combined with zafirlukast on pulmonary function and inflammatory factor of the patients with bronchial asthma. Method According to the time of admission and random number table method, 106 patients with bronchial asthma in our hospital were divided into budesonide + zafirlukast group (budesonide combined with zafirlukast therapy) and budesonide group (budesonide treatment alone), two groups of patients were treated with routine treatment of asthma, 7 days for a course of treatment, a total of 2 courses of treatment. Result FEV1, FEV1/FVC and PEF of budesonide +zafirlukast group were higher than budesonide group (P < 0.01). The levels of IL-4、IL-8 and TNF-α of budesonide + zafirlukast group were lower than budesonide group (P < 0.01). The total effective rate of budesonide + zafirlukast group was higher than budesonide group (P < 0.01). Conclusion Budesonide combined with zafirlukast can improve pulmonary ventilation function of patients with bronchial asthma and reduce the levels of inflammatory factors, and improve asthma symptoms.
展开▼
